Adial Q2 net loss widens to $51.99 million from year-ago quarter
ADIL•Pipeline focus shifts to AT177
Pipeline focus shifted to AT177 for ulcerative colitis after the Azora acquisition. The company targets an IND filing in Q2 2027 and expects a proof-of-concept readout in H1 2028.
Cash position and operating outflows
Cash and cash equivalents totaled $28.7 million at June 30, 2026.
Net cash used in operations rose to $7.98 million.
Costs rise while research spending declines
General and administrative costs more than quadrupled to $5.4 million on merger-related costs, bonus and severance.
Research and development expenses fell 40% to $440,000.
Quarterly loss widens on acquisition-related charge
Adial posted a GAAP net loss of $51.99 million for the quarter ended June 30, 2026, versus a $1.96 million loss a year earlier.
Operating loss widened to from , driven by a acquired in-process R&D charge.
